Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly pegvisomant dosing in controlled acromegaly
2004-004904-19Phase 4Completed
- Sponsor
- The Christie
- Start
- May 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegvisomant in acromegaly, sponsored by The Christie. Primary endpoint: Weekly dose of pegvisomant required to normalize IGF-I. Started May 2005; status: completed.
02
Drugs
pegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2004-004904-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004904-19.